Paul W. Manley

18.1k total citations · 2 hit papers
153 papers, 10.6k citations indexed

About

Paul W. Manley is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Paul W. Manley has authored 153 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Hematology, 54 papers in Genetics and 42 papers in Rheumatology. Recurrent topics in Paul W. Manley's work include Chronic Myeloid Leukemia Treatments (88 papers), Chronic Lymphocytic Leukemia Research (49 papers) and Eosinophilic Disorders and Syndromes (42 papers). Paul W. Manley is often cited by papers focused on Chronic Myeloid Leukemia Treatments (88 papers), Chronic Lymphocytic Leukemia Research (49 papers) and Eosinophilic Disorders and Syndromes (42 papers). Paul W. Manley collaborates with scholars based in Switzerland, United States and Germany. Paul W. Manley's co-authors include Sandra W. Cowan‐Jacob, James D. Griffin, Jürgen Mestan, Doriano Fabbro, Ellen Weisberg, Thomas Meyer, Andreas Hochhaus, Pascal Furet, Gabriele Fendrich and Arghya Ray and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Paul W. Manley

148 papers receiving 10.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Paul W. Manley, James D. Griffin et al. profile →
In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

2005 812 citations Thomas O’Hare, Denise K. Walters et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul W. Manley Switzerland	50	5.9k	4.2k	3.4k	2.7k	2.0k	153	10.6k
Carlo Gambacorti‐Passerini Italy	56	7.9k 1.3×	5.5k 1.3×	5.0k 1.5×	3.3k 1.2×	2.9k 1.5×	342	13.7k
Elisabeth Buchdunger Switzerland	42	8.7k 1.5×	5.6k 1.3×	5.7k 1.7×	3.9k 1.4×	4.4k 2.3×	60	17.4k
J. Zimmermann Switzerland	27	3.3k 0.6×	2.1k 0.5×	2.0k 0.6×	1.5k 0.5×	1.0k 0.5×	48	6.2k
Michael W. Deininger United States	67	16.3k 2.8×	12.5k 2.9×	4.9k 1.4×	7.5k 2.8×	3.2k 1.6×	399	21.2k
Martin Sattler United States	55	3.1k 0.5×	1.5k 0.4×	4.3k 1.3×	578 0.2×	2.4k 1.2×	151	8.6k
Omar Abdel‐Wahab United States	68	7.4k 1.2×	5.3k 1.2×	10.9k 3.2×	1.4k 0.5×	2.2k 1.1×	306	18.6k
Giuseppe Saglio Italy	75	18.5k 3.1×	13.4k 3.2×	5.6k 1.7×	7.0k 2.6×	4.3k 2.2×	650	25.0k
Thomas Meyer Switzerland	45	1.5k 0.3×	961 0.2×	3.7k 1.1×	446 0.2×	2.2k 1.1×	137	7.9k
George W. Muller United States	45	5.1k 0.9×	1.3k 0.3×	4.9k 1.4×	227 0.1×	2.9k 1.5×	83	8.8k
Varsha Gandhi United States	60	3.8k 0.6×	4.1k 1.0×	6.2k 1.8×	166 0.1×	3.7k 1.9×	311	13.5k

Countries citing papers authored by Paul W. Manley

Since Specialization

Citations

This map shows the geographic impact of Paul W. Manley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul W. Manley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul W. Manley more than expected).

Fields of papers citing papers by Paul W. Manley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul W. Manley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul W. Manley. The network helps show where Paul W. Manley may publish in the future.

Co-authorship network of co-authors of Paul W. Manley

This figure shows the co-authorship network connecting the top 25 collaborators of Paul W. Manley. A scholar is included among the top collaborators of Paul W. Manley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul W. Manley. Paul W. Manley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoch, Matthias, Felix Huth, Paul W. Manley, et al.. (2024). Clinical Pharmacology of Asciminib: A Review. Clinical Pharmacokinetics. 63(11). 1513–1528. 7 indexed citations

Palmer, Suetonia C., et al.. (2024). Graft Loss in Pediatric and Young Adult Kidney Transplantation in New Zealand: Who Is at Greatest Risk and When?. Pediatric Transplantation. 28(7). e14873–e14873.

Schöffski, Patrick, Yemarshet K. Gebreyohannes, Thomas Van Looy, et al.. (2022). In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. Biomedicines. 10(5). 1135–1135. 5 indexed citations

Stone, Richard M., Paul W. Manley, Richard A. Larson, & Renaud Capdeville. (2018). Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Advances. 2(4). 444–453. 113 indexed citations

Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2014). Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research. 20(23). 6071–6082. 42 indexed citations

Corbin, Amie S., Thomas O’Hare, Zhimin Gu, et al.. (2013). KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. Cancer Research. 73(18). 5775–5786. 17 indexed citations

White, Deborah L., Jerald P. Radich, Simona Soverini, et al.. (2011). Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 97(6). 907–914. 44 indexed citations

Cullinane, Carleen, Anthony Natoli, Nelly Conus, et al.. (2010). Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model. Molecular Cancer Therapeutics. 9(5). 1461–1468. 27 indexed citations

Mahon, François‐Xavier, Sandrine Hayette, Valérie Lagarde, et al.. (2008). Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression. Cancer Research. 68(23). 9809–9816. 174 indexed citations

10.

Vajpai, Navratna, André Strauss, Gabriele Fendrich, et al.. (2008). Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib. Biomolecular NMR Assignments. 2(1). 41–42. 22 indexed citations

11.

Steadman, Robert, Paul W. Manley, Kathrine J. Craig, et al.. (2008). Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis.. PubMed. 23(6). 731–9. 49 indexed citations

12.

Day, Elizabeth, Katrin Spiegel, Paul W. Manley, et al.. (2008). Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. European Journal of Pharmacology. 599(1-3). 44–53. 224 indexed citations

13.

White, Deborah L., Verity A Saunders, Phuong Dang, et al.. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110(12). 4064–4072. 244 indexed citations

14.

Manley, Paul W., Josef Brüggen, Doriano Fabbro, Georg Martiny‐Baron, & Thomas Meyer. (2007). Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Cancer Research. 67. 3249–3249. 9 indexed citations

15.

White, Deborah L., et al.. (2007). Proton pump inhibitors interact with transport of both imatinib and nilotinib.. Cancer Research. 67. 1635–1635. 1 indexed citations

16.

Weisberg, Ellen, Paul W. Manley, J. Mestan, et al.. (2006). AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer. 94(12). 1765–1769. 364 indexed citations

17.

Prenen, Hans, Gunther Guetens, Gert De Boeck, et al.. (2006). Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines. Pharmacology. 77(1). 11–16. 55 indexed citations

18.

O’Hare, Thomas, Denise K. Walters, Eric P. Stoffregen, et al.. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 65(11). 4500–4505. 812 indexed citations breakdown →

19.

Manley, Paul W., Jürgen Mestan, Sandra W. Cowan‐Jacob, et al.. (2005). AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase. Cancer Research. 65. 1408–1408. 2 indexed citations

20.

Manley, Paul W., Juergen Mestan, Thomas Meyer, & Doriano Fabbro. (2004). An ELISA for PDGFR phosphorylation: Comparison of effects of STI571 on cellular Bcr-Abl, c-Kit and PDGFR-β protein kinases. Cancer Research. 64. 345–346. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact